Solid dispersions containing kinase inhibitors

US8557995B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Jonathan M. Miller
• Rajeev Gokhale · Waukegan, US
• Eric A. Schmitt · Libertyville, US
• Yi Gao · Vernon Hills, US
• Justin S. Lafountaine · Chicago, US
• Lloyd S. Dias · Gurnee, US

Key dates

• Filing date: Jun 7, 2011
• Grant date: Oct 15, 2013
• Expiry date: Jul 1, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/2077
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A solid dispersion comprises, in essentially non-crystalline form, a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a cancer.